Clinical and immunological factors associated with bullous pemphigoid relapse.

JAMA Dermatol

Division of Dermatology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee2Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee.

Published: January 2014

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamadermatol.2013.8090DOI Listing

Publication Analysis

Top Keywords

clinical immunological
4
immunological factors
4
factors associated
4
associated bullous
4
bullous pemphigoid
4
pemphigoid relapse
4
clinical
1
factors
1
associated
1
bullous
1

Similar Publications

Use of immunocontraception in the regulation of male goat sexual activity.

Pol J Vet Sci

September 2024

Ruminant and Swine Clinic, Faculty of Veterinary Medicine, Veterinary University Brno, Palackého třída 1946/1, 612 42 Brno, Czech Republic.

This study focused on continuous monitoring of the immunocontraceptive effect of Improvac® vaccine on the sexual activity of male goats determined by measuring plasma testosterone levels, testicular biometric and ejaculate examination. The animals in the experimental group (n=12) were administered two doses of 2 ml of Improvac® at a four-week interval; the animals in the control group (n=5) received 2 ml of saline. Blood collection, semen collection and testicular measurements were performed at 14-day intervals.

View Article and Find Full Text PDF

Systematic review: differences in complete blood count component rhythms.

Sleep Adv

December 2024

Department of Allergy, Division of Pediatric Allergy and Immunology, Ann & Robert H. Lurie Children's Hospital, Chicago, IL, USA.

Study Objectives: The complete blood count (CBC) is one of the most commonly ordered blood tests with a large range of reference values that does not consider time of day for interpretation. Our objective was to systematically review this topic to report on peak and trough timing of CBC values.

Methods: A systematic search was performed for studies evaluating any component of the CBC with at least three collections over 24 hours.

View Article and Find Full Text PDF

Background: Immune checkpoint inhibitors play an important role in the treatment of solid tumors, but the currently used immune checkpoint inhibitors targeting programmed cell death-1 (PD-1), programmed cell death ligand-1 (PD-L1), and cytotoxic T-lymphocyte antigen-4 (CTLA-4) show limited clinical efficacy in many breast cancers. B7H3 has been widely reported as an immunosuppressive molecule, but its immunological function in breast cancer patients remains unclear.

Methods: We analyzed the expression of B7H3 in breast cancer samples using data from the Cancer Genome Atlas Program (TCGA) and the Gene Expression Omnibus (GEO) databases.

View Article and Find Full Text PDF

Background: Immune checkpoint inhibitors (ICIs) are effective in a subset of patients with metastatic solid tumors. However, the patients who would benefit most from ICIs in biliary tract cancer (BTC) are still controversial.

Materials And Methods: We molecularly characterized tissues and blood from 32 patients with metastatic BTC treated with the ICI pembrolizumab as second-line therapy.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!